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Abstract 
We evaluated the pharmacokinetics and efficacy of oral mycophenolate mofetil (MMF) 
for treatment of refractory graft-versus-host disease (GVHD).  In a prospective study of 
acute GVHD, 9 of 19 patients (47%) had a response and 10 (53%) had no improvement.  
Survival at 6 and 12 months after the start of MMF was 37% and 16%, respectively.  In a 
retrospective study of acute GVHD, 14 of 29 patients (48%) had a response and 15 (52%) 
had no improvement.  Survival at 6 and 12 months was 55% and 52%, respectively.  In a 
prospective study of chronic GVHD, the cumulative incidence of disease resolution and 
withdrawal of all systemic immunosuppressive treatment was 9%, 17% and 26% at 12, 
24 and 36 months after starting MMF, respectively. Thirteen patients (59%) required 
additional systemic immunosuppressive treatment for chronic GVHD.  Nine of the 42 
patients (21%) in the prospective studies discontinued MMF treatment because of 
toxicity.  Area under the curve plasma concentrations of mycophenolic acid appeared to 
be suboptimal among patients with acute GVHD but not among those with chronic 
GVHD.  MMF can be used effectively for treatment of GVHD.             
 2
Introduction 
Acute and chronic graft-versus-host disease (GVHD) are the most common early and late 
complications after allogeneic hematopoietic stem cell transplantation (HCT) and is a 
major cause of morbidity and non-relapse mortality [1,2].  Depending on the degree of 
recipient HLA mismatching, the source of the donor graft and other risk factors, 30 - 80% 
of graft recipients will develop acute GVHD, usually requiring systemic 
immunosuppressive treatment [3-6].  Overall response rates in the range of 24 – 55% 
have been reported after initial therapy with glucocorticoids or other immunosuppressive 
medications [7-12], and many patients require secondary therapy with additional 
immunosuppressive agents.  Overall response rates in the range of 30 – 75% have been 
reported for a variety of agents used for treatment of steroid-resistant or steroid-refractory 
acute GVHD, although transplant-related mortality remains high, even when secondary 
treatment improves GVHD manifestations [13-21].   
 
Depending on the stem cell source and the time of evaluation, approximately 30 - 65% of 
patients develop chronic GVHD after HCT, often requiring long-term glucocorticoid 
treatment [22, 23].  In a large retrospective study, the median duration of treatment for 
chronic GVHD was 23 months [24].  Both acute and chronic GVHD are associated with 
an increased risk of transplant-related mortality, often related to opportunistic infections 
[22, 25].  More effective and less toxic therapies and treatment strategies are needed to 
improve the management of GVHD and decrease morbidity and non-relapse mortality. 
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Mycophenolate mofetil (MMF) is the 2(4-morpholine) ethyl ester of mycophenolic acid 
(MPA).  MMF is rapidly absorbed following oral administration and hydrolyzed to the 
active metabolite, MPA [26].  MPA selectively and reversibly inhibits inosine 
monophosphate dehydrogenase (IMPDH), blocking the de novo pathway of purine 
synthesis in T and B lymphocytes [27-29].  Preclinical studies in allogeneic transplant 
models have shown that MMF has activity in preventing graft rejection and GVHD [30-
33].  After transplantation of unrelated DLA-mismatched marrow in dogs, MMF 
synergizes with cyclosporine (CSP) to prevent GVHD and improve survival [34].  Phase 
III clinical studies after kidney transplantation have shown that MMF is effective in the 
prevention of graft rejection [35-38].  Studies using MMF for treatment of acute and 
chronic GVHD following HCT have reported efficacy in the range of 30 - 90% [39-48].   
 
Two Phase II clinical trials and a retrospective review were conducted to evaluate the 
safety and efficacy of oral MMF for treatment of acute and chronic GVHD.  Since 
gastrointestinal toxicity from the conditioning regimen or gut involvement from acute 
GVHD might affect the absorption of oral MMF, plasma levels of MPA were measured 
in order to assess differences between acute and chronic GVHD and to determine the 
optimal dosing of MMF for treatment of GVHD. 
 
Patients and Methods 
Patient enrollment in these two prospective clinical trials began in November 1995 and 
was completed in December 1997.  The Institutional Review Board (IRB) at Fred 
Hutchinson Cancer Research Center (FHCRC) approved the trials, and all patients signed 
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consent documents.  Patients were approached sequentially for enrollment in each of 
these trials, provided they met the eligibility criteria summarized below.  The original 
plan was to enroll 20 patients in each study.  
 
For purposes of comparison and validation, results were retrospectively reviewed for all 
patients who received MMF for secondary therapy of acute GVHD after initial treatment 
with prednisone following HCT with myeloablative conditioning regimens between 2000 
and 2005.  This analysis was also approved by the FHCRC IRB.    
 
Patients 
The primary therapy for acute GVHD was prednisone or methylprednisolone, initially at 
2 mg/kg/day, in addition to continued administration of cyclosporine (CSP) originally 
prescribed for prophylaxis.  Patients with acute GVHD were eligible for the acute GVHD 
study (AGVHD Group) if GVHD manifestations worsened after 3 days of primary 
therapy, showed no improvement after 7 days, or persisted for more than 14 days.  
Patients with skin or gastrointestinal involvement had to have biopsy-proven evidence of 
GVHD.   
 
Initial treatment for chronic GVHD was prednisone at 1 mg/kg/day, in addition to 
continued administration of CSP or tacrolimus (TAC).  Patients with extensive chronic 
GVHD were eligible for the chronic GVHD study (CGVHD Group) if GVHD 
manifestations 1) worsened or showed no improvement after at least 2 months of initial 
treatment, 2) persisted after at least 9 months of treatment in patients with “high risk” 
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chronic GVHD (progressive onset or platelet count < 100,000/mm3 at onset),  3) or for at 
least 18 months of treatment in patients with “standard risk” chronic GVHD, or 4) if 
GVHD manifestations recurred during a taper of steroid doses.     
 
Patients were excluded from participation in either study if they were unable to tolerate 
oral therapy, if the neutrophil count was less than 1500/uL or if they had evidence of 
recurrent malignancy.  Patients with a serum creatinine concentration >2.0 mg/dL were 
excluded from participation in the acute GVHD study, and those with a creatinine 
clearance <30 ml/min were excluded from the chronic GVHD study.   
 
Treatment Plan and Supportive Care 
All study patients received the oral formulation of MMF at an initial dose of 1 gram twice 
daily for adults and 20 mg/kg/day twice daily for patients who weighed less than 50 
kilograms.  For patients in the AGVHD Group, the dose of MMF could be increased to 
1.5 grams twice daily if GVHD manifestations had worsened at study day 7 or had not 
improved by study day 14.  The protocol recommended adjustments in the dose of MMF 
if hematopoietic or gastrointestinal toxicity was suspected.  Recommendations were to 
decrease the MMF dose by 50% if the neutrophil count decreased to <1000/uL, and to 
discontinue administration of MMF if the neutrophil count decreased to <750/uL.  
Additional recommendations were to decrease the dose of MMF if patients developed 
gastrointestinal problems not caused by GVHD and to discontinue administration of 
MMF if problems persisted afterwards.   
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For patients in the AGVHD Group, MMF was administered for 35 days.  Treatment with 
MMF was discontinued if GVHD resolved or there was no response by study day 35.  
Treatment with MMF could be continued beyond 35 days in patients with a partial 
response and in those with recurrent GVHD after treatment with MMF was discontinued.  
Glucocorticoid doses were tapered at the discretion of the attending physician.  For 
patients in the retrospective AGVHD Group, the decision to start MMF therapy, the 
dosing and route of administration, and the duration of therapy were determined by the 
attending physician.          
 
For treatment of CGVHD, MMF was administered for 9-12 months.  Treatment with 
MMF was discontinued if GVHD manifestations resolved.  If GVHD manifestations 
improved but persisted after 9-12 months, treatment with MMF was continued for 
another 9-12 months.  If GVHD manifestations showed no improvement or worsened 
after 2 months, treatment with MMF was discontinued.  In the absence of toxicity, 
administration of CSP or TAC was continued during the initial period of treatment with 
MMF. 
 
All protocol patients received antifungal prophylaxis with fluconazole.  All 
cytomegalovirus (CMV)-seropositive patients had weekly testing for reactivation of 
CMV, and pre-emptive therapy with ganciclovir was initiated, when appropriate.  
Patients received prophylaxis against Pneumocystis pneumonia with trimethoprim 
(TMP)/sulfamethoxazole (SMX).  Dapsone was given to patients who could not tolerate 
TMP/SMX. 
 7
 Pharmacokinetics 
Plasma levels of MPA, the active metabolite of MMF, were measured on days 1, 7 and 
35 after the start of MMF therapy.  Day 1 sampling was started before administration of 
the first dose of MMF.  Specimens were collected immediately before and at 1, 2, 4, 8, 
and 12 hours after ingestion of MMF.  Blood was collected in tubes containing EDTA.  
Blood was centrifuged at 4° C and the plasma was collected.  Plasma was stored at -70 C 
and shipped to the University of Alberta, Canada, for analysis.  MPA plasma levels were 
quantified by HPLC and peak plasma concentration (Cmax) and area-under-the-curve 
(AUC) were determined as described previously [49]. 
 
Evaluation of response 
The evaluation and grading of acute and chronic GVHD has been described previously 
[1,2,50].  Treatment responses in the AGVHD Group were categorized as a complete 
response, a partial response or a treatment failure.  A complete response was defined as 
the absence of any symptoms related to GVHD, with no additional agents needed to 
control the disease.  A partial response was defined as improvement of at least one stage 
in severity of acute GVHD in one organ without deterioration in any other organ.  
Treatment failure was defined as the absence of improvement, deterioration of acute 
GVHD in any organ by at least one stage, the development of GVHD manifestations in a 
previously unaffected organ, or the use of any additional agents to control the disease.  
Patients were scored for best response at any time after starting treatment with MMF, 
with follow-up censored at the onset of any subsequent systemic immunosuppressive 
 8
therapy.  This criterion was also used to assess response to treatment with MMF for 
patients in the retrospective AGVHD Group. 
 
Responses in the CGVHD Group were measured according to two outcomes.  Failure 
was defined as the use of any additional agents to control GVHD within 3 years after 
starting treatment with MMF, including resumption of treatment with agents used 
previously or the substitution of one calcineurin inhibitor for the other.  Success was 
defined as the discontinuation of all systemic immunosuppressive therapy without 
recurrent malignancy within 12, 24 and 36 months after starting treatment with MMF.  
Medications used to treat chronic GVHD were abstracted from records of evaluations in 
Seattle and from correspondence with the referring physician.  In both groups, follow-up 
for evaluation of GVHD was censored at the onset of recurrent malignancy. 
 
Results 
Patient and Transplant Characteristics 
Nineteen patients with acute GVHD and 23 patients with chronic GVHD were enrolled in 
the two prospective studies, and the retrospective analysis included 29 patients (Table 1).  
Compared to the prospective AGVHD Group, the patients in the retrospective AGVHD 
Group were older (median age, 40 years versus 20 years), were more likely to have low-
risk hematologic malignancies (52% versus 32%), had a higher proportion of unrelated 
(93% versus 53%) and HLA-mismatched donors (45% versus 37%), and a higher 
proportion received peripheral blood stem cell grafts (69% versus 21%).  Approximately 
half of the patients in the CGVHD Group had unrelated donors.  Most patients in the 
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CGVHD Group had low-risk hematologic diseases at the time of transplant and received 
bone marrow grafts.  Three patients in the CGVHD Group and one in the prospective 
AGVHD Group had previous allogeneic HCT.  None of the patients in the retrospective 
acute GVHD Group had previous HCT. 
 
Treatment Response – AGVHD Groups 
In the prospective study, the median onset of acute GVHD was 10 days after HCT (range 
5 – 30) (Table 2).  MMF therapy was started at a median of 42 days after transplantation 
and 31 days after the diagnosis of acute GVHD.  The median duration of MMF 
administration was 35 days (range 3 – 416).  Seventeen patients received glucocorticoids 
as initial treatment for acute GVHD and two patients received CSP.  Three patients had 
received one additional systemic immunosuppressive therapy for acute GVHD before 
starting treatment with MMF.  In this group, 6 of 19 patients (31%) had complete 
resolution of acute GVHD, 3 (16%) had partial responses, and 10 (53%) had no 
improvement.  In 3 patients, treatment with MMF was stopped after 3 days because of 
progressive GVHD.  One of these patients had no further treatment, and the other 2 were 
treated with antithymocyte globulin.  All 3 died within 12 days. At the start of treatment 
with MMF, 12 patients (63%) had Grade II GVHD, 5 (26%) had Grade III GVHD and 2 
(11%) had Grade IV GVHD.  Eight of the 12 patients (67%) with Grade II GVHD at the 
start of MMF therapy had a complete or partial response, compared to only 1 of the 7 
patients (14%) with Grades III – IV GVHD.  All but one of the 14 patients surviving 
beyond 100 days after HCT developed chronic GVHD. 
 
 10
In comparing the retrospective AGVHD Group with the prospective AGVHD Group, the 
main differences were a lower incidence of Grade III-IV GVHD at the onset of MMF 
therapy (14% versus 37%), and longer median times from HCT to the onset of treatment 
with MMF (52 days versus 42 days), from initial diagnosis of GVHD to the onset of 
treatment with MMF (42 days versus 31 days), and from the onset of steroid treatment to 
the onset of treatment with MMF (35 days versus 24 days) (Table 2).  Patients in the 
retrospective AGVHD Group had a lower incidence of gastrointestinal (38% versus 53%) 
and hepatic (24% versus 32%) GVHD.  There were no differences in the time of onset of 
GVHD or the clinical response to MMF.  In this group, 9 of 29 patients (31%) had 
complete response, 5 (17%) had partial response, and 15 (52%) had no improvement.  
Despite the differences in GVHD severity and interval times at onset of MMF therapy, 
the response rates in the two AGVHD groups were virtually identical.  Seventy-nine 
percent of the patients in the restrospective AGVHD Group were initially treated with the 
oral formulation of MMF.  All patients in the prospective AGVHD Group were treated 
exclusively with the oral formulation.      
 
Treatment Response – CGVHD Group 
Treatment with MMF was started at a median of 20 months after HCT (Table 3).  MMF 
was administered for a median of 12 months (range 3 – 99).  Sixteen of the 23 patients 
(70%) had received at least one systemic immunosuppressive therapy for chronic GVHD 
in addition to glucocorticoids and the original prophylactic calcineurin inhibitor before 
starting treatment with MMF.  Seven patients had received tacrolimus, six had received 
azathioprine, and 4 had received thalidomide.  When MMF therapy was started, most 
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patients were receiving combination immunosuppressive therapy with a calcineurin 
inhibitor plus glucocorticoids.  Nine patients had chronic GVHD involving two organs 
and 10 had chronic GVHD affecting 3 or more organs, most often involving the skin and 
the oral cavity. 
 
At 12, 24 and 36 months after the start of MMF therapy 2 (9%), 4 (17%) and 6 (26%) 
patients, respectively, had discontinued all immunosuppressive therapy after resolution of 
chronic GVHD at 9 – 35 (median, 22) months after starting treatment with MMF (Figure 
2).  Two patients could not be evaluated at 12 months.  One had died, and the other had 
recurrent malignancy.  At 24 and 36-months, 7 additional patients could not be evaluated.  
One was lost to follow-up, one had recurrent malignancy, and 5 had died. None of the 
patients who died or had recurrent malignancy had discontinued immunosuppressive 
treatment after resolution of GVHD.  Thirteen of the 22 patients (59%) with follow-up 
information required additional therapy for chronic GVHD within three years after 
starting treatment with MMF.  One patient was lost to follow-up and could not be 
evaluated.                                 
 
Toxicity and Early Discontinuation of MMF 
Eight patients in the prospective AGVHD Group discontinued treatment with MMF 
before day 35 (Table 4).  Three had progressive GVHD and discontinued treatment with 
MMF after 3 days, and one other patient died on day 29.  Administration of MMF was 
discontinued in 4 patients because of neutropenia (n = 2), abdominal pain (n = 1) or 
pulmonary infiltrate (n = 1).  Doses of MMF were reduced in 3 other patients because of 
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neutropenia or presumed gastrointestinal toxicity.  In the CGVHD Group, 11 patients 
discontinued administration of MMF prematurely due to gastrointestinal discomfort (n = 
4), neutropenia (n = 1), lack of efficacy (n = 4) or recurrent malignancy (n = 2).  Doses of 
MMF were reduced in one patient because of presumed gastrointestinal toxicity. 
Altogether, 9 of the 42 patients (21%) in the two prospective studies discontinued MMF 
treatment because of toxicity.    
 
Pharmacokinetics 
Pharmacokinetic testing was completed in twelve patients in the prospective AGVHD 
Group and 18 in the CGVHD Group.  On day 2 (median; range, 1-10) after starting 
treatment with MMF, the median MPA-AUC was 15.8 (range, 7.6-25.3; mean 17.1 +/- 
5.5) μg x hr/mL in the AGVHD Group, compared to 49.9 (range, 19.2-202.8; mean 62.0 
+/- 47.9) μg x hr/mL on day 2 (median; range, 1-13) in the CGVHD Group (Wilcoxon, 
p<0.0001)).  The median Cmax was 4.8 (range, 1.8-8.6; mean 5.1 +/- 2.3) μg/mL in the 
AGVHD Group compared to 12.0 (range, 5.8-24.7; mean 12.8 +/- 5.7) in the CGVHD 
Group (Wilcoxon, p<0.0001).  
 
Outcome 
In the prospective AGVHD Group, 7 (37%) and 3 (16%) patients were alive at 6 and 12 
months, respectively, after starting treatment with MMF.  Two patients (11%) died with 
recurrent malignancy on days 119 and 182, respectively, after starting treatment with 
MMF.  These results contrast with survival rates of 55% and 52% at 6 and 12 months, 
respectively, in the retrospective AGVHD Group (Figure 1).  Two patients (7%) died 
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with recurrent malignancy respectively on days 126 and 158 after starting treatment with 
MMF.  In the CGVHD Group, 22 patients (96%) were alive one year after starting 
treatment with MMF (Figure 2). Twelve of 23 (52%) patients with follow-up 
information remain alive at 7.9 – 10.6 (median, 9.5) years after starting treatment with 
MMF.  One of these patients is still being treated with immunosuppressive medications at 
the time of last follow-up.  Three patients had recurrent malignancy after treatment with 
MMF therapy. Causes of death for all prospective study patients are listed in Table 5.  In 
the retrospective group, fungal infection was implicated in six of seven patients who died 
with infection, compared to 3 of 6 patients who died with infection in the prospective 
group.  Overall, the causes of death between the groups were not different. 
 
Discussion 
A requirement for additional therapy beyond glucocorticoids to treat acute or chronic 
GVHD identifies a group of patients with generally poor outcomes. Historically, 
antithymocyte globulin has been commonly used to treat refractory acute GVHD 
[14,20,21,51,52], but a variety of new immunosuppressive agents have been evaluated 
more recently [15-19,52,53,54].  Depending on the definition of response and time of 
evaluation, response rates range from 30–75%, but survival has been poor, even in 
studies with high response rates.  Survival rates are difficult to evaluate in these studies 
because many reports did not show Kaplan-Meier estimates of survival across time.  
Mortality was commonly associated with uncontrolled GVHD, often complicated by 
opportunistic infection.         
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A few reports have described the use of MMF for treatment of refractory acute GVHD in 
small numbers of patients [40,41,46-48].  Comparisons with our experience are 
complicated by differences in patient selection, the degree of immunosuppression at the 
beginning of treatment with MMF, definitions of response and the timing of evaluations.  
It is unknown whether the patients described in these reports were treated with the 
parenteral formulation of MMF.  In our studies only the oral formulation of MMF was 
used.  The overall combined response and survival rates among the 42 patients included 
in these reports is 48% and 38%, respectively.  In our prospective study of acute GVHD, 
the clinical response rate was 47%, but survival at 6 and 12 months after starting 
treatment with MMF was only 37% and 16%, respectively. Only 2 patients died with 
recurrent hematologic malignancy.  In the retrospective AGVHD Group, the clinical 
response rate was nearly identical, although the 6 and 12 month survival rates were 55% 
and 52%, respectively.  Two patients died with recurrent hematologic malignancy.   
 
The early onset of acute GVHD in the prospective and retrospective studies of acute 
GVHD was somewhat unusual and could raise some question about the accuracy of the 
initial diagnosis, especially since engraftment syndrome can mimic acute GVHD.  
Engraftment syndrome generally resolves during short-term treatment with high-dose 
glucocorticoids, whereas GVHD generally resolves more slowly.  The persistence of 
inflammatory manifestations despite initial glucocorticoid treatment suggests that our 
patients had GVHD rather than engraftment syndrome.  
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The poor 6 and 12 month survival rates in the prospective acute GVHD study, which was 
completed in the mid-1990s, prompted a retrospective review of more recent experience 
with the use of MMF for treatment of steroid-resistant acute GVHD, since MMF is now 
widely used for secondary treatment of acute GVHD.  Reasons for the difference in 
survival between the two AGVHD groups are not entirely clear.  Although the median 
age of the prospective AGVHD Group was lower and a higher proportion had HLA-
matched related donors, this group also contained higher proportions of patients with 
high-risk malignancies and Grades III - IV GVHD at the start of MMF therapy.  Three 
patients in the prospective AGVHD Group had progressive GVHD requiring additional 
immunosuppressive therapy and died within 12 days after starting treatment with MMF.  
The shorter interval times from HCT, diagnosis of GVHD and initiation of prednisone 
treatment to onset of treatment with MMF suggest more aggressive progression of 
GVHD and greater glucocorticoid resistance in the prospective cohort compared to the 
retrospective cohort.  The similarity of response rates in the two groups, however, argues 
against this supposition.  The favorable survival among patients in the retrospective 
AGVHD Group may reflect improved management of GVHD, longer experience with the 
use of MMF, and the availability of the intravenous formulation, although most patients 
in the retrospective group were treated initially with the oral formulation.   
 
One could argue that differences in survival between the two AGVHD groups might be 
attributable to advances in transplantation during the years when these groups were 
treated.  Patients in the prospective group had HCT in 1995-1997, while patients in the 
retrospective group had HCT in 2000-2005.  The latter group might have benefited from 
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improved primary treatment regimens, such as combination therapy with busulfan and 
cyclophosphamide.  Ten patients (35%) in the retrospective AGVHD Group received this 
combination of chemotherapy, compared to none in the prospective AGVHD Group.  The 
proportion of patients in the retrospective AGVHD Group who received growth factor-
mobilized blood cells was higher in the retrospective AGVHD group than in the 
retrospective AGVHD group (69% versus 21%).  The use of mobilized blood cells likely 
resulted in earlier neutrophil engraftment and may have influenced immune 
reconstitution.   Newer antibiotic therapies, particularly for the treatment for fungal 
infections, were more readily available to patients in the recent cohort.  This potential 
advantage was not validated, however, since the proportions of patients who died with 
infections were not strikingly different in the two groups.             
 
A variety of agents have been used to treat refractory chronic GVHD [55-59], and 
response rates with the use of MMF have been approximately 40 – 90% [42-45].  Lopez 
et al. [43] reported on 34 patients who received MMF therapy for treatment of chronic 
GVHD.  Responses were observed in 9 of 10 patients who received MMF for initial 
treatment of chronic GVHD and in 18 of 24 patients who received MMF as secondary 
treatment for persistent or progressive chronic GVHD.  At a median follow-up of 24 
months, 22 of the 30 patients (73%) treated with glucocorticoids at the start of MMF 
therapy were able to reduce the dose of glucocorticoids, although only one patient was 
able to discontinue glucocorticoid treatment. The number of patients requiring additional 
agents to treat chronic GVHD after starting MMF therapy is not reported.  Twenty-nine 
patients (85%) were alive at the time of the analysis.  Addition of MMF to a calcineurin 
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inhibitor and glucocorticoids produced 17 complete responses (65%) among 26 pediatric 
patients with refractory chronic GVHD [45].  Treatment with MMF was started at a 
median of 14 months after HCT, and all patients with improvement were able to 
discontinue treatment with MMF within 3 years.  The number of patients who were able 
to discontinue all immunosuppressive therapy is not reported.  Twenty-two patients 
(85%) were alive at a median of 4.7 years after HCT.   
 
In the current study, most patients had received a variety of agents in addition to a 
calcineurin inhibitor and glucocorticoids for management of chronic GVHD before 
beginning treatment with MMF.  Also, the median time from HCT to the beginning of 
treatment with MMF was nearly 20 months, suggesting that this group of patients may 
have had more resistant chronic GVHD.  Despite these unfavorable risk factors, the 96% 
1-year survival of the CGVHD Group compares favorably with the results of other 
studies reporting the use of MMF for first or second-line treatment of chronic GVHD.  
The 5-year survival rate was 74%, which is similar to patients with newly diagnosed 
“standard risk” chronic GVHD [60].  The rate of discontinuation of all 
immunosuppressive treatment at 1-, 2- and 3-years after the start of MMF in the CGVHD 
Group compares favorably with historical results.  Even more impressive is the 
observation that the 26% 3-year cumulative incidence of discontinued 
immunosuppressive treatment after resolution of chronic GVHD was comparable to 
historical results in patients with newly diagnosed chronic GVHD [24].    
 
 18
The ability to administer treatment over a prolonged period of time and the availability of 
an intravenous and oral formulation are advantages for the use of MMF, allowing for 
multi-agent therapy, particularly for chronic GVHD.  Although treatment with MMF was 
scheduled to stop after 35 days in the acute GVHD study, 6 patients continued treatment 
for more than 35 days.  In the CGVHD Group, the median duration of MMF therapy was 
11.6 months.  Consistent with previous reports, most patients showed good tolerance to 
MMF therapy, although 4 patients in the AGVHD Group and 5 in the CGVHD Group 
discontinued treatment with MMF therapy prematurely because of suspected toxicity 
generally related to gastrointestinal complaints and neutropenia.  The rate of 
discontinuation reflects, in part, the fact that safety concerns were of prime importance in 
these early studies investigating the use of MMF for treatment of GVHD.  Since 
experience was limited, investigators had a low threshold in deciding to discontinue 
administration of MMF.  As the use of MMF has expanded, for both treatment and 
prophylaxis, dose adjustments are more likely the first step to managing potential 
toxicities, before discontinuing administration of MMF.  A direct causal link between 
MMF treatment and the toxicities observed in these studies could not always be made. In 
some cases, adverse effects had multiple causes, particularly when administration of 
MMF was discontinued because of cytopenia or gastrointestinal complaints, which occur 
frequently after HCT even in the absence of treatment with MMF.           
 
At the time these studies were conducted, only the oral formulation of MMF was 
available.  Pharmacokinetic analysis indicates that the AUC and Cmax of MPA were 
lower in patients in the prospective AGVHD Group compared to the CGVHD Group, 
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possibly due to reduced bioavailability or interference with the enterohepatic 
recirculation.  Ten of 19 patients in the AGVHD Group had evidence of gastrointestinal 
GVHD when MMF therapy was started.   Low levels of MPA and decreased 
bioavailability after administration of oral MMF have been noted previously in acute 
GVHD prevention studies [61,62].  In a study evaluating MPA levels after the 
administration of oral MMF for initial treatment of acute GVHD, Kiehl et al. [63] 
reported lower MPA levels among patients with gastrointestinal GVHD compared to 
those with skin GVHD.  This difference was not noted in our small sampling of patients 
who had pharmacokinetic sampling performed.  They also observed that trough plasma 
MPA concentrations were higher among patients with improvement in GVHD 
manifestations than among those who had no improvement. 
 
The standard dose of MMF at our center for treatment of acute GVHD is 30 mg/kg/day in 
divided doses, or approximately 1 gram twice daily.  In renal transplant studies, the AUC 
of MPA after oral administration predicts allograft rejection among patient receiving 
cyclosporine [64,65].  In these pharmacokinetic studies, an increased MMF dose 
correlated with an increased AUC of MPA.  van Gelder et al. [64] showed that after 
kidney transplantation, day 7 mean MPA AUC levels of 17, 27 and 43.9 μg x hr/mL 
resulted in biopsy-proven acute rejection rates of 28, 15 and 12 %, respectively.  
Similarly, Hale et al. [65] found that an MPA AUC of 15, 25 and 40 μg x h/mL yielded 
efficacy rates of 50%, 75% and 90% following kidney transplantation.  The median MPA 
AUC within 10 days after the start of MMF in our prospective AGVHD study was only 
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15.8 μg x hr/mL.  The MPA AUC among patients with chronic GVHD was consistent 
with results from solid organ transplant recipients.              
 
Oral MMF can be used successfully for treatment of refractory acute and chronic GVHD.  
The long-term survival rate in the prospective AGVHD Group was low, although more 
recent experience using MMF as secondary treatment is more encouraging.  The 
difference should be interpreted with caution, since the improved outcome in the more 
recent cohort of patients is based on a retrospective analysis.  The challenge remains to 
control the response of donor cells against recipient alloantigens, while at the same time 
allowing protective immune responses against pathogens.  Results with the use of MMF 
for treatment of steroid-refractory chronic GVHD have encouraged the development of 
phase III trials to establish the benefits and risks of MMF or MPA for initial treatment of 
chronic GVHD.    
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Table 1.  Patient and Transplant Characteristics According to Treatment Group 
 AGVHD  
Characteristic 
Prospective 
Group         
(n = 19) 
Retrospective 
Group         
(n = 29) 
CGVHD 
Group         
(n = 23) 
Patient age, median years (range) 20 (4 - 54) 40 (2 - 61) 27 (2 - 57) 
Disease risk, n (%)1    
     Low 6 (32) 15 (52) 15 
     High 13 (68) 14 (48) 8 
Donor type and recipient HLA-matching, n (%)    
     Related donor    
          HLA-matched 5 (26) 2 (7) 10 
          HLA-mismatched 4 (21) 0 (0) 3 
     Unrelated donor    
          HLA-matched 7 (37) 14 (48) 4 
          HLA-mismatched 3 (16) 13 (45) 6 
Stem cell source, n (%)2      
     Marrow 16 (84) 9 (31) 21 
     Peripheral blood stem cells 4 (21) 20 (69) 2 
Conditioning regimen, n (%)    
     Cyclophosphamide/TBI 6 (32) 14 (48) 13 
     Busulfan/cyclophosphamide 0 (0) 10 (35) 6 
     Busulfan/TBI 5 (26) 0 (0) 0 
     Other 8 (42) 5 (17) 4 
GVHD prophylaxis, n (%)    
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     Cyclosporine/methotrexate 15 (78) 23 (80) 16 
     Tacrolimus/methotrexate 0 (0) 3 (10) 0 
     Cyclosporine/prednisone 2 (11) 0 (0) 2 
     Other 2 (11) 3 (10) 5 
1Low-risk disease included chronic myelogenous leukemia in chronic phase; acute leukemia in 
first remission; refractory anemia without excess blasts; and lymphoma in first remission, first 
untreated relapse or second remission.  Three patients with thalassemia, Chediak-Higashi 
syndrome and paroxysmal nocturnal hemoglobinuria were included in the low risk category.   
2 One patient in the prospective AGVHD Group received peripheral blood stem cells and marrow. 
     
Table 2. Acute GVHD Characteristics and Treatment Responses    
Characteristic 
Prospective 
Group        
(n = 19) 
Retrospective 
Group         
(n = 29) 
Onset of acute GVHD, median day after HCT (range) 10 (5 - 30) 11 (5 - 34) 
Acute GVHD grade at start of MMF therapy, n (%)   
     I 0 (0) 3 (10) 
     II 12 (63) 22 (76) 
     III 5 (26) 4 (14) 
     IV 2 (11) 0 (0) 
Organ involvement at the start of MMF therapy, n (%)   
     Skin 13 (68) 22 (76) 
     Gastrointestinal 10 (53) 11 (38) 
     Hepatic 6 (32) 7 (24) 
Start of MMF therapy, median day (range)   
     From HCT 42 (27 - 89) 52 (22 - 131) 
     From diagnosis of acute GVHD 31 (14 - 79) 42 (13 - 120) 
     From start of primary therapy 24 (9 - 68) 35 (4 - 121) 
Clinical response, n (%)   
     Complete response 6 (31) 9 (31) 
     Partial response 3 (16) 5 (17) 
     Treatment failure 10 (53) 15 (52) 
Subsequent chronic GVHD, n (%)   
     Yes 13 (93) 22 (88) 
     No 1 (7) 3 (12) 
     Not evaluated 5 4 
 Table 3.  Chronic GVHD Characteristics and Treatment Responses 
Characteristic 
CGVHD Group 
(n = 23) 
Months from transplantation to start of MMF, median (range)  20 (4 – 91) 
Number of prior chronic GVHD therapies, n   
     1 13 
     2 3 
     None 7 
Affected sites at the start of treatment with MMF, n  
     Skin 18 
     Oral 18 
     Eyes 9 
     Gastrointestinal tract 4 
     Lung 4 
     Liver 4 
     Vagina 1 
Number of sites involved at the start of treatment with MMF, n  
     1 4 
     2 9 
     3 6 
     More than 3 4 
Immunosuppressive therapy (IS) at study enrollment, n  
     CSP or tacrolimus plus glucocorticoids 14 
     Glucocorticoids alone  4 
     CSP or tacrolimus alone  2 
     Other 3 
Months of treatment with MMF, median (range)2 12 (3 – 99) 
Patients who discontinued all immunosuppressive treatment, n (%)1  
     12 months 2 (9) 
     24 months 4 (17) 
     36 months 6 (26) 
Months to discontinuation of immunosuppressive treatment, median (range) 22 (9 – 35) 
Patients requiring additional treatment for GVHD after MMF, n (%)2 13 (59) 
1Two patients could not be evaluated at 12 months, 9 at 24 months and 9 at 36 months.   
2One patient was lost to follow-up and could not be evaluated.  
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Table 4. Reasons for Early Discontinuation of Treatment with MMF 
Reason 
Prospective 
AGVHD Group     
(n = 19)  
CGVHD Group       
(n = 23)* 
Death 1  0 
Cytopenia 2  1 
Gastrointestinal toxicity 1  4 
Pulmonary infiltrates 1  0 
Uncontrolled GVHD 3  4 
Recurrent malignancy 0  2 
*One patient was lost to follow-up   
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 Table 5.  Causes of Death    
Cause 
Prospective 
AGVHD Group     
(n = 19) 
Retrospective  
AGVHD Group 
(n = 29) 
CGVHD 
Group     
(n = 23) 
Respiratory failure (not infection) 1 2 5 
Infection 6 7 3 
Recurrent malignancy 3 1 0 
Cardiopulmonary 2 0 1 
GVHD 4 5 1 
Multi-organ failure 1 0 1 
Secondary malignancy 0 1 0 
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Titles and legends to figures 
 
Figure 1.  Overall survival in the prospective (solid line) and retrospective (dashed line) 
AGVHD Groups. 
 
Figure 2.  Overall survival and duration of immunosuppression in the CGVHD Group.  
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